At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 66 enrolled
Drug / intervention
Ivermectindrug
Likely dose
Ivermectin 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management
In Brief
A Phase 3 clinical trial evaluating Ivermectin for COVID-19. Completed, enrolled 66 participants across 4 sites.
Detailed Summary
In this multicenter study; it was aimed to investigate the effectiveness and safety of ivermectin use in the treatment of patients with severe COVID-19 pneumonia that have no mutations which alter ivermectin metabolism and cause side effects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesTurkey (Türkiye)
CollaboratorsNeuTec Pharma
Timeline
Phase 3CompletedFinished
202120222023202420252026
Enrollment StartMay 2020
Primary CompletionSep 2020
First PostedNov 2020
TodayJul 2026
First PostedNov 27, 2020
Enrollment StartMay 11, 2020
Primary CompletionSep 2, 2020
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.6 years ago
Interventions
Ivermectindrug
Ivermectin 5mg/5ml solution was manufactured by NEUTEC™ Pharmaceutical Company-Turkey, under "Good Manufacturing Practices" (GMP) certification conditions.